Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41401-020-0438-y http://scihub22266oqcxt.onion/10.1038/s41401-020-0438-y 32555446!7298161!32555446     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32555446&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Pharmacol+Sin 2020 ; 41 (9): 1133-1140 Nephropedia Template TP {{tp|p=32555446|t=2020. Overview of therapeutic drug research for COVID-19 in China |pdf=|usr=}}{{32555446}} gab.com Text Overview of therapeutic drug research for COVID-19 in China JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=32555446 #FOAvip Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed. Twit Text FOAVip Overview of therapeutic drug research for COVID-19 in China ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=32555446 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32555446 #FOAvip English Wikipedia <ref>{{Cite pmid|32555446}}</ref> Overview of therapeutic drug research for COVID-19 in China #MMPMID32555446 Li H; Yang L; Liu FF; Ma XN; He PL; Tang W; Tong XK; Zuo JP Acta Pharmacol Sin 2020[Sep]; 41 (9): 1133-1140 PMID32555446show ga Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19. According to the information that we have collected so far, this article provides an overview of potential therapeutic drugs and compounds with much attention, including favipiravir and hydroxychloroquine, as well as traditional Chinese medicine, which have been reported with good clinical treatment effects. Moreover, with further understanding of SARS-CoV-2 virus, new drugs targeting specific SARS-CoV-2 viral components arise and investigations on these novel anti-SARS-CoV-2 agents are also reviewed. |*Coronavirus Infections/drug therapy/physiopathology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy/etiology/physiopathology[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/*drug effects/physiology[MESH] |COVID-19[MESH] |Clinical Protocols[MESH] |Humans[MESH] |Medicine, Chinese Traditional/*methods[MESH]Overview of therapeutic drug research for COVID-19 in China (epmc).pdf DeepDyve Pubget Overpricing